BeOne Medicines (BEIGF) Net Margin (2015 - 2026)

BeOne Medicines (BEIGF) has reported Net Margin for 12 consecutive years, with 13.9% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Margin rose 673.0% year-over-year to 13.9% in Q2 2026; TTM through Jun 2026 was 10.7%, a 1459.0% increase from a year earlier, with the FY2025 full-year figure at 5.37%, up 2229.0% from the prior year.
• Net Margin was 13.9% for Q2 2026 at BeOne Medicines, down from 15.02% in the prior quarter.
• Over five years, Net Margin peaked at 27.57% in Q3 2023 and troughed at 165.62% in Q2 2022.
• A 5-year average of 42.4% and a median of 13.21% in 2024 frame the typical range for Net Margin.
• Across the five-year window, Net Margin plunged 15291 bps in 2022 and surged 17141 bps in 2023, its largest moves.
• Over 5 years, Net Margin stood at 117.16% in 2022, then soared by 51 bps to 57.94% in 2023, then surged by 77 bps to 13.47% in 2024, then jumped by 133 bps to 4.44% in 2025, then surged by 213 bps to 13.9% in 2026.
• The last three Net Margin figures came in at 13.9% (Q2 2026), 15.02% (Q1 2026), and 4.44% (Q4 2025), per Business Quant data.